StockData

ClearPoint Neuro vs Lensar

CLPT and LNSR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CLPT and LNSR compare

ClearPoint Neuro is the larger company, worth 4.4 times as much as Lensar ($272M against $61.4M).

ClearPoint Neuro grew revenue faster over the last twelve months (32.5% versus 1.6% for Lensar).

Lensar keeps more of each dollar of sales as profit, with a net margin of 56.1% compared with −79.4% at ClearPoint Neuro.

Lensar scores higher on the StockData Score (7 against 4 for ClearPoint Neuro), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCLPTLNSR
Size and price
Market cap$272M$61.4M
Share price$8.48$5.00
Change, 1 year−49.3%−52.0%
Change, 5 years−40.8%−29.6%
Beta (5Y)1.810.59
Employees172150
StockData Score
Total score47 (better)
Valuation score01 (better)
Growth score3 (better)2
Performance score02 (better)
Health score12 (better)
Dividend score00
Valuation
P/S6.0×1.0× (better)
P/B10.0×5.6× (better)
FCF yield−17.7%–
Fair value$7.04$5.93
Margin of safety−20.5%15.7% (better)
Growth
Revenue growth (TTM)32.5% (better)1.6%
Revenue growth, 5Y average23.6% (better)17.2%
Profitability
Gross margin61.4% (better)52.0%
Operating margin−70.6%−3.3% (better)
Net margin−79.4%56.1% (better)
FCF margin−106%–
Return on equity−168%–
Return on invested capital−131%–
Financial health
Debt / equity1.860.17 (better)
Interest coverage−6.0×–
Current ratio6.76 (better)2.25
Altman Z-score−1.07−0.86 (better)
Piotroski F-score5 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions43.4%36.0%
Held by insiders3.6%–
Insider net buying, 12 months−$2.5M–
Short interest, % of float13.9%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.